Cardiorenalmetabolic

A Brown University–led review synthesizes GDMT, comorbidity management, and emerging therapies into a hospital-based framework for HFpEF.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Children of mothers with poor cardiovascular health during pregnancy had nearly double the risk of developmental delay at age 4.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and clinical framework it demands.

The CHG index predicted CKM syndrome onset, progression, and adverse outcomes, suggesting a simple tool for risk stratification across disease stages.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver disease screening.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

Real-world EHR study shows PREVENT equations deliver reliable CVD risk prediction despite missing data, guiding smarter outreach and recalibration.

Focal segmental glomerulosclerosis can lead to protein leakage in urine and hypertension; the condition is not considered curable at present, only manageable.

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Tirzepatide was associated with a significant reduction in a composite of major cardiovascular and kidney outcomes vs the GLP-1 agonist dulaglutide.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

A program in Detroit identified hundreds of patients with chronic kidney disease.

Pediatric health coaching offers a workforce-driven solution to provide support that traditional care models often lack, with the potential to improve outcomes and reduce long-term costs.

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.